799 related articles for article (PubMed ID: 15860260)
1. p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.
Liang Y; Wu J; Stancel GM; Hyder SM
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):173-82. PubMed ID: 15860260
[TBL] [Abstract][Full Text] [Related]
2. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
Menendez JA; Oza BP; Colomer R; Lupu R
Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
[TBL] [Abstract][Full Text] [Related]
3. Progestin regulation of vascular endothelial growth factor in human breast cancer cells.
Hyder SM; Murthy L; Stancel GM
Cancer Res; 1998 Feb; 58(3):392-5. PubMed ID: 9458078
[TBL] [Abstract][Full Text] [Related]
4. Curcumin inhibits MPA-induced secretion of VEGF from T47-D human breast cancer cells.
Carroll CE; Ellersieck MR; Hyder SM
Menopause; 2008; 15(3):570-4. PubMed ID: 18467956
[TBL] [Abstract][Full Text] [Related]
5. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
6. Regulation of thrombospondin-1 by natural and synthetic progestins in human breast cancer cells.
Hyder SM; Liang Y; Wu J; Welbern V
Endocr Relat Cancer; 2009 Sep; 16(3):809-17. PubMed ID: 19570906
[TBL] [Abstract][Full Text] [Related]
7. Effect of 17 beta-estradiol, progesterone, synthetic progestins, tibolone, and tibolone metabolites on vascular endothelial growth factor mRNA in breast cancer cells.
Mirkin S; Wong BC; Archer DF
Fertil Steril; 2005 Aug; 84(2):485-91. PubMed ID: 16084894
[TBL] [Abstract][Full Text] [Related]
8. Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells.
Kawai H; Li H; Chun P; Avraham S; Avraham HK
Oncogene; 2002 Oct; 21(50):7730-9. PubMed ID: 12400015
[TBL] [Abstract][Full Text] [Related]
9. Ligand- and cell-specific effects of signal transduction pathway inhibitors on progestin-induced vascular endothelial growth factor levels in human breast cancer cells.
Wu J; Brandt S; Hyder SM
Mol Endocrinol; 2005 Feb; 19(2):312-26. PubMed ID: 15528272
[TBL] [Abstract][Full Text] [Related]
10. Cyproterone, norethindrone, medroxyprogesterone and levonorgestrel are less potent local human growth hormone and insulin-like growth factor I secretion stimulators than progesterone in human breast cancer explants expressing the estrogen receptor.
Milewicz T; Kolodziejczyk J; Krzysiek J; Basta A; Sztefko K; Kurek S; Stachura J; Gregoraszczuk EL
Gynecol Endocrinol; 2002 Aug; 16(4):319-29. PubMed ID: 12396561
[TBL] [Abstract][Full Text] [Related]
11. Estrogen regulation of vascular endothelial growth factor gene expression in ZR-75 breast cancer cells through interaction of estrogen receptor alpha and SP proteins.
Stoner M; Wormke M; Saville B; Samudio I; Qin C; Abdelrahim M; Safe S
Oncogene; 2004 Feb; 23(5):1052-63. PubMed ID: 14647449
[TBL] [Abstract][Full Text] [Related]
12. Progestin-dependent induction of vascular endothelial growth factor in human breast cancer cells: preferential regulation by progesterone receptor B.
Wu J; Richer J; Horwitz KB; Hyder SM
Cancer Res; 2004 Mar; 64(6):2238-44. PubMed ID: 15026368
[TBL] [Abstract][Full Text] [Related]
13. Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma.
Pal S; Datta K; Mukhopadhyay D
Cancer Res; 2001 Sep; 61(18):6952-7. PubMed ID: 11559575
[TBL] [Abstract][Full Text] [Related]
14. Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics.
Liang Y; Besch-Williford C; Brekken RA; Hyder SM
Cancer Res; 2007 Oct; 67(20):9929-36. PubMed ID: 17942925
[TBL] [Abstract][Full Text] [Related]
15. Distinct promoter usage of mdm2 gene in human breast cancer.
Okumura N; Saji S; Eguchi H; Nakashima S; Saji S; Hayashi S
Oncol Rep; 2002; 9(3):557-63. PubMed ID: 11956627
[TBL] [Abstract][Full Text] [Related]
16. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion.
Mehta SA; Christopherson KW; Bhat-Nakshatri P; Goulet RJ; Broxmeyer HE; Kopelovich L; Nakshatri H
Oncogene; 2007 May; 26(23):3329-37. PubMed ID: 17130833
[TBL] [Abstract][Full Text] [Related]
17. Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene.
Casey G; Lo-Hsueh M; Lopez ME; Vogelstein B; Stanbridge EJ
Oncogene; 1991 Oct; 6(10):1791-7. PubMed ID: 1923504
[TBL] [Abstract][Full Text] [Related]
18. Genetic instability and the development of steroid hormone insensitivity in cultured T 47D human breast cancer cells.
Reddel RR; Alexander IE; Koga M; Shine J; Sutherland RL
Cancer Res; 1988 Aug; 48(15):4340-7. PubMed ID: 3390830
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms involved in the evolution of progestin resistance in human breast cancer cells.
Murphy LC; Dotzlaw H; Wong MS; Miller T; Murphy LJ
Cancer Res; 1991 Apr; 51(8):2051-7. PubMed ID: 1849041
[TBL] [Abstract][Full Text] [Related]
20. Estradiol-induced vascular endothelial growth factor-A expression in breast tumor cells is biphasic and regulated by estrogen receptor-alpha dependent pathway.
Sengupta K; Banerjee S; Saxena N; Banerjee SK
Int J Oncol; 2003 Mar; 22(3):609-14. PubMed ID: 12579315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
